Tag Archives: Real Parties-in-Interest

Time Bar Challenge Must Be Raised before the Board, Not Saved for Appeal

By Michael R. Weiner on Posted in Real Party-in-Interest, Trial Procedures
Since the Federal Circuit’s 2018 en banc decision in Wi-Fi One, LLC v. Broadcom Corporation, (discussed here) the court has reviewed a number of PTAB decisions on whether an IPR petition was filed more than one year after the petitioner was served with a complaint asserting the challenged patent, and thus time-barred under 35 U.S.C. … Continue Reading

Petitioner Has Burden of Persuasion on Real Party in Interest

By Michael R. Weiner on Posted in Discovery, Real Party-in-Interest, Trial Procedures
Under 35 U.S.C. § 312(a), an IPR petition must identify “all real parties in interest,” and, an IPR petition is time-barred under 35 U.S.C. § 315(b) if “filed more than 1 year after the date on which the petitioner, the real party in interest, or a privy of the petitioner is served with a complaint alleging … Continue Reading

Federal Circuit Upholds Board’s Use of Control Standard of Privity to Assess Time Bar

By Marshall Gerstein on Posted in Inter Partes Review, Real Party-in-Interest
It is undisputed that institution of an inter partes review (IPR) is time-barred under 35 U.S.C. § 315(b) if the petition is “filed more than 1 year after the date on which the petitioner, the real party in interest, or a privy of the petitioner is served with a complaint alleging infringement of the patent. The … Continue Reading

Federal Circuit Affirms Tribal Sovereign Immunity Does Not Apply to IPR

By Lynn L. Janulis, Ph.D. on Posted in Appeals, Inter Partes Review, IPR, Real Party-in-Interest
The Federal Circuit recently affirmed the PTAB’s decision that tribal immunity cannot be asserted in an IPR (Saint Regis Mohawk Tribe v. Mylan Pharma Inc., Case No. 2018-1638 (Fed. Cir. July 20, 2018). On appeal, Allergan, Inc. (“Allergan”) argued that the Board improperly denied its motion to withdraw from IPR proceedings, and the Saint Regis … Continue Reading

Federal Circuit Admonishes PTAB for Taking Short-cuts

By Sandip H. Patel on Posted in Institution / Denial, Inter Partes Review, Real Party-in-Interest
In Application in Internet Time v. RPX Corp., Nos. 2017-1698, -1699, -1701 (Fed. Cir. July 9, 2018), the Federal Circuit decided that the Patent Trial and Appeal Board “applied an unduly restrictive test for determining whether a person or entity is a ‘real party in interest’ within the meaning of [35 USC] § 315(b) and … Continue Reading

Federal Circuit Requests Briefing from Patent Office Regarding § 315(b) Time-Bar Determinations

By Ryan N. Phelan on Posted in Appeals, Inter Partes Review, IPR, Real Party-in-Interest, Trial Procedures
On June 7, 2018, the Federal Circuit in Wi-Fi One, LLC v. Broadcom Corp. requested that intervenor, Patent Office director Andrei Iancu, and appellee Broadcom, file a response to Wi-Fi One’s second petition for rehearing.  Wi-Fi One, Case No. 2015-1944, Docket No. 212 (June 7, 2018).  At issue was whether the court should grant Wi-Fi … Continue Reading

Tribal Sovereign Immunity Alone Cannot Protect Patents from IPR

By Lynn L. Janulis, Ph.D. on Posted in Appeals, Inter Partes Review, Real Party-in-Interest
In late March, the Federal Circuit issued an order staying the PTAB proceedings concerning numerous related IPRs of patents issued to Allergan, Inc. (“Allergan”), but assigned to the Saint Regis Mohawk Tribe (“the Tribe”). These IPRs were headed toward a final hearing on the merits previously scheduled for April 3rd. In those IPRs, the PTAB denied the Tribe’s … Continue Reading

Enactment of the STRONGER Patents Act Would Severely Limit PTAB Proceedings

By Sharon M. Sintich, Ph.D. on Posted in Amendments, Appeals, Discovery, Estoppel, Institution / Denial, Inter Partes Review, IPR, Legislation, Post Grant Review, Real Party-in-Interest, Stays, Trial Procedures
The STRONGER (Support Technology & Research for Our Nation’s Growth and Economic Resilience) Patents Act of 2017 was recently introduced in the Senate.  The Act is an updated version of the STRONG Patents Act of 2015 that stalled in Congress.  Like its predecessor, the STRONGER Patents Act is designed to significantly modify the AIA trial … Continue Reading

Guidance on Requesting Motions for Sanctions

By Sharon M. Sintich, Ph.D. on Posted in Covered Business Method, Discovery, Inter Partes Review, IPR, Real Party-in-Interest, Trial Procedures
On November 10, 2016, the Intellectual Property Owners Association (IPO) hosted a panel discussion entitled Ethics in AIA Post-Grant Proceedings at the PTAB with the Honorable Thomas Giannetti, Lead Administrative Patent Judge of the PTAB. The main topic of the discussion was guidance on motions for sanctions.  The rules relating to trial practice before the … Continue Reading

PTAB Upholds Claims Under Narrowed BRI Construction on Remand

By Ryan N. Phelan on Posted in Claim Construction, Inter Partes Review
The PTAB’s recent decision on remand in Corning Optical Comm. v. PPC Broadband (IPR2013-00342, Paper No. 57), and the related decision on appeal (815 F.3d 747 (Fed. Cir. 2016)), serve as a reminder that the broadest reasonable interpretation (BRI) standard does not permit an unreasonably broad construction. In addition, the PTAB’s related order (see Paper … Continue Reading

PTAB’s Reconsideration of Institution Decision Unreviewable on Appeal

By Michael R. Weiner on Posted in Appeals, Institution / Denial, Inter Partes Review, IPR, Real Party-in-Interest
In denying a petition for rehearing, the Federal Circuit determined in Medtronic, Inc. v. Robert Bosch Healthcare Systems, Inc. that under Cuozzo, the court lacks authority to review a PTAB decision that reconsidered an IPR institution decision, and then terminated the IPR because the petition failed to identify the real party in interest. As we have … Continue Reading

The Personal Touch: PTAB Grants Bass and Spangenberg IPR Petition

thumbnail image of DNA strandBy Eric M. Brusca, Ph.D. on Posted in Biotechnology, Inter Partes Review, Real Party-in-Interest, Sections 102/103
On May 20, 2016, the PTAB granted Kyle Bass and Erich Spangenberg’s petition for IPR (IPR2016-00245) against a patent owned by Alpex Pharma SA (Alpex).  The petition sought cancellation of claims 1-9 of U.S. Patent No. 8,440,170, asserting that the claims were obvious in view of numerous references.  The claims of the ‘170 patent are generally … Continue Reading

PTAB Provides Procedural Guidance with Five Precedential Opinions

By Marshall Gerstein on Posted in Amendments, Discovery, Real Party-in-Interest, Trial Procedures
Update: The Supreme Court issued a decision on April 20, 2020  holding that the patent statute (35 U.S.C. § 314(d)) bars judicial review of a PTAB decision of whether an inter partes review petition is time-barred pursuant to 35 USC 315(b). As stated by the Court, the PTAB’s “application of §315(b)’s time limit, we hold, is … Continue Reading

Coalition for Affordable Drugs PTAB Scorecard

By Katherine L. Neville, Ph.D. on Posted in Institution / Denial, Inter Partes Review
In the ongoing saga of the Coalition for Affordable Drugs (CFAD) vs. the pharmaceutical industry, there has been quite a bit of movement recently by the PTAB on institution of many of CFAD’s earliest-filed IPR petitions.  To date, CFAD has filed 33 petitions for IPR, some of them multiple petitions against the same patent, and … Continue Reading

PTAB Denies Institution of Two IPR Petitions Filed by Hedge Fund

thumbnail image of DNA strandBy Eric M. Brusca, Ph.D. on Posted in Biotechnology, Institution / Denial, Inter Partes Review, Legislation, Real Party-in-Interest, Sections 102/103
As the patent community anxiously awaits the PTAB’s decision concerning whether the Coalition For Affordable Drugs (CFAD) should be sanctioned for filing an IPR petition against a Celgene patent¹, the PTAB recently denied institution of two IPR petitions² the CFAD filed concerning two Acorda patents that cover Ampyra, a billion-dollar drug for treating multiple sclerosis.  The … Continue Reading

Suppliers Can Lack Standing to Seek CBM Review on Behalf of Customers

By Thomas L. Duston on Posted in Covered Business Method, Institution / Denial
In several recent decisions, the PTAB has clarified the standing required to file petitions seeking Covered Business Method review.  Under the AIA, standing to seek Covered Business Method review is limited to those charged with infringement and their “privies.”  “Privies,” however, do not encompass merely any party with whom the petitioner is in “privity.”  “Privies” … Continue Reading

Is the Coalition for Affordable Drugs Abusing the IPR Process?

By Julianne M. Hartzell on Posted in Institution / Denial, Inter Partes Review, Legislation, Real Party-in-Interest, Sections 102/103
The PTAB granted leave on June 9 for the patent owner, Celgene Corporation, to file a motion for sanctions seeking dismissal in several IPRs¹ filed by the Coalition for Affordable Drugs. The Coalition for Affordable Drugs, an organization created by the hedge fund Hayman Credes Master Fund L.P., has filed multiple IPRs against pharmaceutical companies with … Continue Reading

Real Party-In-Interest Not Necessarily Established by Co-Defendants in Litigation

By Eric M. Brusca, Ph.D. on Posted in Inter Partes Review, Real Party-in-Interest
Whether a non-identified party is a real party-in-interest to a proceeding is a highly fact-dependent question. Office Patent Trial Practice Guide, 77 Fed. Reg. 48,756, 48,759 (Aug. 14, 2012) (“Trial Practice Guide”) (citing Taylor v. Sturgell, 553 U.S. 880 (2008)).  “A common consideration is whether the non-party exercised or could have exercised control over a … Continue Reading
LexBlog